Free Trial

National Vision (EYE) Stock Forecast & Price Target

National Vision logo
$11.07 -0.22 (-1.95%)
(As of 11/13/2024 ET)

National Vision - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
1

Based on 3 Wall Street analysts who have issued ratings for National Vision in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a buy rating for EYE.

Consensus Price Target

$14.00
26.47% Upside
According to the 3 analysts' twelve-month price targets for National Vision, the average price target is $14.00. The highest price target for EYE is $18.00, while the lowest price target for EYE is $11.00. The average price target represents a forecasted upside of 26.47% from the current price of $11.07.
Get the Latest News and Ratings for EYE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for National Vision and its competitors.

Sign Up

EYE Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24
1 Month Ago
10/16/23 to 10/15/24
3 Months Ago
8/17/23 to 8/16/24
1 Year Ago
11/15/22 to 11/15/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$14.00$15.25$15.25$26.78
Forecasted Upside26.47% Upside48.20% Upside37.14% Upside37.25% Upside
Consensus Rating
Hold
Hold
Hold
Hold

EYE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EYE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

National Vision Stock vs. The Competition

TypeNational VisionMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.80
2.50
Consensus RatingHoldModerate BuyHold
Predicted Upside26.47% Upside26,278.21% Upside8.03% Upside
News Sentiment Rating
Positive News

See Recent EYE News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2024The Goldman Sachs Group
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$20.00 ➝ $13.00+18.83%
8/8/2024Barclays
3 of 5 stars
 Lower TargetEqual Weight ➝ Equal Weight$16.00 ➝ $11.00+4.17%
8/8/2024UBS Group
4 of 5 stars
 Lower TargetBuy ➝ Buy$20.00 ➝ $18.00+65.14%
11/13/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $19.00+6.56%
7/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$28.00 ➝ $22.00-11.15%
7/27/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$30.00 ➝ $21.00-15.19%
5/12/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$23.00 ➝ $28.00+17.85%
5/4/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $34.00+55.11%
11/16/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$45.00+12.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:27 AM ET.


EYE Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for National Vision is $14.00, with a high forecast of $18.00 and a low forecast of $11.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for National Vision in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EYE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EYE, but not buy additional shares or sell existing shares.

According to analysts, National Vision's stock has a predicted upside of 26.47% based on their 12-month stock forecasts.

Analysts like National Vision less than other "medical" companies. The consensus rating for National Vision is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EYE compares to other companies.


This page (NASDAQ:EYE) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners